LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Chiusa

SettoreSettore sanitario

15.44 2.86

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15.02

Massimo

15.49

Metriche Chiave
By Trading Economics
Entrata	-130B -25B
Vendite	-99B 1.1T
P/E Media del settore	39.974 49.888
EPS	0.21
Rendimento da dividendi	4.35
Margine di Profitto	-2.222
Dipendenti	47,455
EBITDA	-242B 214B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+39.72% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	4.35% 2.38%

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-3.7B 48B
Apertura precedente	12.58
Chiusura precedente	15.44

Notizie sul Sentiment di mercato

By Acuity

100%

325 / 344 Classifica in Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2026, 08:59 UTC

Utili

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 gen 2026, 07:11 UTC

Utili

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 dic 2025, 03:32 UTC

I principali Market Mover

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 ott 2025, 09:39 UTC

Utili

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 ott 2025, 07:32 UTC

Utili

Takeda Posts Quarterly Net Loss, Cuts Guidance

13 mag 2026, 06:57 UTC

Utili

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 mag 2026, 06:54 UTC

Utili

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 mag 2026, 06:44 UTC

Utili

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 mag 2026, 06:38 UTC

Utili

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 mag 2026, 06:31 UTC

Utili

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 mag 2026, 06:31 UTC

Utili

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mag 2026, 06:31 UTC

Utili

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 mag 2026, 06:31 UTC

Utili

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 mag 2026, 06:31 UTC

Utili

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mag 2026, 06:31 UTC

Utili

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 gen 2026, 06:53 UTC

Utili

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 gen 2026, 06:36 UTC

Utili

Takeda Raises FY Revenue, Net-Profit Views

29 gen 2026, 06:34 UTC

Utili

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 gen 2026, 06:33 UTC

Utili

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 gen 2026, 06:32 UTC

Utili

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 ott 2025, 07:10 UTC

Utili

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 ott 2025, 06:50 UTC

Utili

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 ott 2025, 06:49 UTC

Utili

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 ott 2025, 06:48 UTC

Utili

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Confronto tra pari

Modifica del prezzo

Takeda Pharmaceutical Co Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

39.72% in crescita

Previsioni per 12 mesi

Media 21 USD 39.72%

Alto 21 USD

Basso 21 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Takeda Pharmaceutical Co Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Takeda Pharmaceutical Co Ltd ADR - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.